← Leaderboards
John G Bartlett
Johns Hopkins University
$1,448,360
Attributed
$1,448,360
Total exposure
16
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$9,145,509 · 17
By mechanism
P30$7,697,149 · 2
U01$1,304,490 · 1
T32$143,870 · 1
M01$0 · 13
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Charles W. Flexner$41,000,447
- Joshua D Nosanchuk$4,457,092
- Ryan Loren Peterson$1,202,922
- Ned C Sacktor$10,719,879
- Kyle W Cunningham$5,999,195
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHuman Therapy EvaluationDrug Screening /EvaluationAidsHiv InfectionsAids TherapyAntiaids AgentCombination ChemotherapyAntiviral AgentsLamivudineVirus LoadZidovudineMycobacterium TuberculosisClinical Trial Phase INucleoside AnalogOpportunistic InfectionsReverse Transcriptase InhibitorsMedical ComplicationDelavirdineBiomedical FacilityPharmacokineticsMicroorganism Disease ChemotherapyIndinavir
Grant awards (50)
JOHNS HOPKINS CENTER FOR AIDS RESEARCH$617,020
P30 · FY2005 · AI
JOHNS HOPKINS CENTER FOR AIDS RESEARCH$1,480,849
P30 · FY2004 · AI
JOHNS HOPKINS CENTER FOR AIDS RESEARCH$1,451,207
P30 · FY2003 · AI
JOHNS HOPKINS CENTER FOR AIDS RESEARCH$1,297,313
P30 · FY2002 · AI
ACTG 382--HI PROTEIN SUPPLEMENTS IN HIV+ WEIGHT LOSS PTS$0
M01 · FY2002 · RR
INDINAVIR IN COMBO WITH NUCLEOSIDE ANALOGS IN HIV$0
M01 · FY2002 · RR
ACTG 370--3TC VS DLV IN COMBO WITH IDV AND ZDV/D4T$0
M01 · FY2002 · RR
ACTG 265--STEADY STATE PHARMACOKINETIC INTERACTION OF INDINAVIR AND RIFABUTIN$0
M01 · FY2002 · RR
ACTG 372--PHASE II STUDY OF PROLONGATION OF VIROLOGIC SUCCESS$0
M01 · FY2002 · RR
ACTG 362--AZITHROMYCIN THERAPY FOR PRIMARY PREVENTION OF MYOCBACTERIUM AVIUM$0
M01 · FY2002 · RR
ACTG 307--VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE VS DEL$0
M01 · FY2002 · RR
ACTG 323--PHASE IV OPEN LABEL COMPARING CHRONIC SUPPRESSIVE THERAPY$0
M01 · FY2002 · RR
ACTG 177--PROPHYLAXIS AGAINST MYCOBACTERIUM TUBERCULOSIS IN PATIENTS WITH HIV$0
M01 · FY2002 · RR
ACTG 359--ACTIVITY OF SOFT GELATIN CAPSULE OF SAQUINAVIR IN COMBINATION$0
M01 · FY2002 · RR
ACTG 364--COMPARISON OF VIROLOGIC EFFICACY OF NELFINAVIR AND OR DMP 266$0
M01 · FY2002 · RR
ACTG 368--RANDOMIZED PHASE II PLACEBO CONTROLLED TRIAL OF 1592U85$0
M01 · FY2002 · RR
SCREENING CONSENT--AIDS CLINICAL TRIALS UNIT$0
M01 · FY2002 · RR
CORE--CLINICAL RESOURCE$0
P30 · FY2002 · AI
JOHNS HOPKINS CENTER FOR AIDS RESEARCH$1,385,401
P30 · FY2001 · AI
CORE--CLINICAL RESOURCE$0
P30 · FY2001 · AI
ACTG 177--PROPHYLAXIS AGAINST MYCOBACTERIUM TUBERCULOSIS IN PATIENTS WITH HIV$0
M01 · FY2001 · RR
ACTG 323--PHASE IV OPEN LABEL COMPARING CHRONIC SUPPRESSIVE THERAPY$0
M01 · FY2001 · RR
ACTG 368--RANDOMIZED PHASE II PLACEBO CONTROLLED TRIAL OF 1592U85$0
M01 · FY2001 · RR
ACTG 364--COMPARISON OF VIROLOGIC EFFICACY OF NELFINAVIR AND OR DMP 266$0
M01 · FY2001 · RR
ACTG 359--ACTIVITY OF SOFT GELATIN CAPSULE OF SAQUINAVIR IN COMBINATION$0
M01 · FY2001 · RR
ACTG 307--VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE VS DEL$0
M01 · FY2001 · RR
ACTG 362--AZITHROMYCIN THERAPY FOR PRIMARY PREVENTION OF MYOCBACTERIUM AVIUM$0
M01 · FY2001 · RR
ACTG 372--PHASE II STUDY OF PROLONGATION OF VIROLOGIC SUCCESS$0
M01 · FY2001 · RR
ACTG 265--STEADY STATE PHARMACOKINETIC INTERACTION OF INDINAVIR AND RIFABUTIN$0
M01 · FY2001 · RR
ACTG 370--3TC VS DLV IN COMBO WITH IDV AND ZDV/D4T$0
M01 · FY2001 · RR
INDINAVIR IN COMBO WITH NUCLEOSIDE ANALOGS IN HIV$0
M01 · FY2001 · RR
ACTG 382--HI PROTEIN SUPPLEMENTS IN HIV+ WEIGHT LOSS PTS$0
M01 · FY2001 · RR
SCREENING CONSENT--AIDS CLINICAL TRIALS UNIT$0
M01 · FY2001 · RR
JOHNS HOPKINS CENTER FOR AIDS RESEARCH$1,465,359
P30 · FY2000 · AI
JOHNS HOPKINS ADULT AIDS CLINICAL TRIALS UNIT$1,304,490
U01 · FY2000 · AI
RESEARCH TRAINING IN MICROBIAL DISEASES$143,870
T32 · FY2000 · AI
ACTG 372--PHASE II STUDY OF PROLONGATION OF VIROLOGIC SUCCESS$0
M01 · FY2000 · RR
ACTG 362--AZITHROMYCIN THERAPY FOR PRIMARY PREVENTION OF MYOCBACTERIUM AVIUM$0
M01 · FY2000 · RR
ACTG 307--VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE VS DEL$0
M01 · FY2000 · RR
ACTG 359--ACTIVITY OF SOFT GELATIN CAPSULE OF SAQUINAVIR IN COMBINATION$0
M01 · FY2000 · RR
ACTG 364--COMPARISON OF VIROLOGIC EFFICACY OF NELFINAVIR AND OR DMP 266$0
M01 · FY2000 · RR
ACTG 368--RANDOMIZED PHASE II PLACEBO CONTROLLED TRIAL OF 1592U85$0
M01 · FY2000 · RR
ACTG 323--PHASE IV OPEN LABEL COMPARING CHRONIC SUPPRESSIVE THERAPY$0
M01 · FY2000 · RR
ACTG 177--PROPHYLAXIS AGAINST MYCOBACTERIUM TUBERCULOSIS IN PATIENTS WITH HIV$0
M01 · FY2000 · RR
SCREENING CONSENT--AIDS CLINICAL TRIALS UNIT$0
M01 · FY2000 · RR
ACTG 382--HI PROTEIN SUPPLEMENTS IN HIV+ WEIGHT LOSS PTS$0
M01 · FY2000 · RR
ACTG 370--3TC VS DLV IN COMBO WITH IDV AND ZDV/D4T$0
M01 · FY2000 · RR
INDINAVIR IN COMBO WITH NUCLEOSIDE ANALOGS IN HIV$0
M01 · FY2000 · RR
CORE--CLINICAL RESOURCE$0
P30 · FY2000 · AI
ACTG 265--STEADY STATE PHARMACOKINETIC INTERACTION OF INDINAVIR AND RIFABUTIN$0
M01 · FY2000 · RR